Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 anti-CD20 CAR-T cell therapy - PersonGen BioTherapeutics

Next Previous
X
Search
Drug Profile

Anti-CD19 anti-CD20 CAR-T cell therapy - PersonGen BioTherapeutics

Alternative Names: Autologous CD19/CD20-CAR-T cells - PersonGen Biotherapeutics

Latest Information Update: 28 Sep 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PersonGen Biomedicine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-Hodgkin's lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for phase-I development in Haematological-malignancies(In adolescents, In children, In the elderly, In adults) in China (IV, Infusion)
  • 31 Dec 2020 Preclinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (PersonGen BioTherapeutics pipeline, January 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top